Home \|\| About KDR \|\| Weekly Feature Archive
Peplin's skin cancer gel trial a success The Age \|\| May 05, 2006 Early clinical trials of a new gel to treat skin cancer have returned promising results. The gel, developed by Brisbane-based company Peplin, can be rubbed on to the skin to treat certain types of skin cancer. Initial trials show just two applications of the PEP005 Topical gel on two consecutive days cleared up 71 per cent of basal cell carcinomas, or BCCs, the most common type of skin cancer. The trials on 60 people throughout Australia built on an early study by Peplin in 2002 using the common garden weed, petty spurge. "That was a very different study and that was just using the raw sap of petty spurge," said Michael Aldridge, Peplin's managing director and chief executive. "This is the same company and we have now identified the molecule responsible for that activity and we have put that into a formal development program, formulated a gel and developed a manufacturing technology. "We ran a phase one study in the US, two phase-two studies looking at sunspots, and this is our third phase-two study looking at basal cell carcinomas." Mr Aldridge said it was the first time the molecule from petty spurge had been used to treat BCCs, which are usually surgically removed. Article Posted at www.KnowledgeDrivenRevolution.com "We've seen some very, very impressive results," he said. "This is the first time two days of therapy have shown to be effective in clearing skin cancers." Peplin hopes to start phase-three studies of the gel later this year. Australasian College of Dermatologists secretary Stephen Shumack said the results were promising. "It is certainly encouraging," Dr Shumack said. "This is a reasonable sort of result and I think from a dermatological point of view, it is the result that would be worthy of further investigation. "It would be an addition to our current therapy." BCCs develop from cells in the basal layer of the skin and account for 80 per cent of skin cancers. A typical BCC sufferer is an older caucasian with a history of sun exposure. The Cancer Council of Australia says 256,000 Australians were treated for BCCs in 2002. About KDR \| \| Home \| \| Weekly Features Archive	Weekly Weekly Features Archive
In Depth What Is Wrong With Canada Recent 9-11 News Suppressed by the Media Aspartame: The Sweetest Killer The Number 1 Reason YOU became a Slave Knowledge Driven Look at Your Favourite Canadian Political Parties
Archive February March April 2006 26 27 28 29 30 31 01 02 03 04 05 06 07 08 09 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 01 02 03 04 05 06 Weekly Features

Home || About KDR || Weekly Feature Archive

Peplin's skin cancer gel trial a success

The Age || May 05, 2006

Early clinical trials of a new gel to treat skin cancer have returned promising results.

The gel, developed by Brisbane-based company Peplin, can be rubbed on to the skin to treat certain types of skin cancer.

Initial trials show just two applications of the PEP005 Topical gel on two consecutive days cleared up 71 per cent of basal cell carcinomas, or BCCs, the most common type of skin cancer.

The trials on 60 people throughout Australia built on an early study by Peplin in 2002 using the common garden weed, petty spurge.

"That was a very different study and that was just using the raw sap of petty spurge," said Michael Aldridge, Peplin's managing director and chief executive.

"This is the same company and we have now identified the molecule responsible for that activity and we have put that into a formal development program, formulated a gel and developed a manufacturing technology.

"We ran a phase one study in the US, two phase-two studies looking at sunspots, and this is our third phase-two study looking at basal cell carcinomas."

Mr Aldridge said it was the first time the molecule from petty spurge had been used to treat BCCs, which are usually surgically removed.

Article Posted at www.KnowledgeDrivenRevolution.com

"We've seen some very, very impressive results," he said.

"This is the first time two days of therapy have shown to be effective in clearing skin cancers."

Peplin hopes to start phase-three studies of the gel later this year.

Australasian College of Dermatologists secretary Stephen Shumack said the results were promising.

"It is certainly encouraging," Dr Shumack said.

"This is a reasonable sort of result and I think from a dermatological point of view, it is the result that would be worthy of further investigation.

"It would be an addition to our current therapy."

BCCs develop from cells in the basal layer of the skin and account for 80 per cent of skin cancers.

A typical BCC sufferer is an older caucasian with a history of sun exposure.

The Cancer Council of Australia says 256,000 Australians were treated for BCCs in 2002.

Maple Leaf Footer
About KDR | | Home | | Weekly Features Archive